Pten is essential for embryonic development and tumour suppression.

PubWeight™: 13.41‹?› | Rank: Top 0.1% | All-Time Top 10000

🔗 View Article (PMID 9697695)

Published in Nat Genet on August 01, 1998

Authors

A Di Cristofano1, B Pesce, C Cordon-Cardo, P P Pandolfi

Author Affiliations

1: Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, New York, NY 10021, USA.

Articles citing this

(truncated to the top 100)

Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A (2003) 15.59

Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev (2005) 12.15

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A (1999) 11.38

Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59

Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes. Cell (2011) 10.56

Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol (2008) 10.42

DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. Nat Genet (2007) 9.25

FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94

Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88

Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62

The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26

The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A (1998) 6.98

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55

Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83

Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31

Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol (2000) 5.22

NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20

miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95

PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A (1999) 4.90

PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol (2009) 4.83

Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell (2011) 4.49

Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev (2009) 4.43

Roles for Nkx3.1 in prostate development and cancer. Genes Dev (1999) 4.30

Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30

Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev (2000) 4.24

Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature (2009) 4.21

Subtle variations in Pten dose determine cancer susceptibility. Nat Genet (2010) 4.19

Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1999) 4.19

The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1998) 4.18

Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol (2007) 4.16

Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res (2008) 3.99

FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science (2008) 3.78

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell (2009) 3.78

mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol (2004) 3.72

Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68

Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol (2009) 3.67

A continuum model for tumour suppression. Nature (2011) 3.48

A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest (2010) 3.47

Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol (2000) 3.42

Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A (2004) 3.40

Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 3.34

Regulation of microRNA expression and abundance during lymphopoiesis. Immunity (2010) 3.29

Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev (2005) 3.25

Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol (2000) 3.23

Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09

PTEN function: how normal cells control it and tumour cells lose it. Biochem J (2004) 3.06

Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell (2014) 3.05

Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. J Cell Biol (2004) 2.93

Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A (2002) 2.89

Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev (1999) 2.87

A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science (2013) 2.86

The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev (2006) 2.76

mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc Natl Acad Sci U S A (2003) 2.68

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest (2008) 2.68

Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell (2014) 2.66

Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A (2000) 2.65

The tuberous sclerosis complex. Ann N Y Acad Sci (2010) 2.51

Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A (2001) 2.50

A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48

Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol (2002) 2.48

Protean PTEN: form and function. Am J Hum Genet (2002) 2.43

Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med (2008) 2.41

Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell (2012) 2.39

A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci U S A (2008) 2.34

Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev (2003) 2.32

PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res (2009) 2.32

Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci U S A (2000) 2.29

Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function. Cell (2014) 2.25

Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol (1999) 2.21

Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol (2002) 2.15

Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res (2008) 2.15

Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A (2007) 2.11

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer (2015) 2.10

Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium. Proc Natl Acad Sci U S A (2008) 2.07

A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci U S A (1999) 2.05

Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol (2000) 2.05

mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04

PTENα, a PTEN isoform translated through alternative initiation, regulates mitochondrial function and energy metabolism. Cell Metab (2014) 2.01

Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol (2004) 2.01

WWP2 is an E3 ubiquitin ligase for PTEN. Nat Cell Biol (2011) 2.00

Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev (2005) 1.99

The loss of PTEN allows TCR alphabeta lineage thymocytes to bypass IL-7 and Pre-TCR-mediated signaling. J Exp Med (2004) 1.92

PTEN level in tumor suppression: how much is too little? Cancer Res (2011) 1.90

Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell (2003) 1.85

Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A (2010) 1.83

Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol (2002) 1.83

Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg (2006) 1.82

Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2005) 1.73

Pten (phosphatase and tensin homologue gene) haploinsufficiency promotes insulin hypersensitivity. Diabetologia (2006) 1.72

Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res (2013) 1.66

Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J Clin Invest (2003) 1.64

SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res (2010) 1.64

PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol (2007) 1.62

The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res (2009) 1.62

Regulation of the insulin-like developmental pathway of Caenorhabditis elegans by a homolog of the PTEN tumor suppressor gene. Proc Natl Acad Sci U S A (1999) 1.62

PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A (2001) 1.62

Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A (2007) 1.61

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer (2006) 1.61

Articles by these authors

Role of the INK4a locus in tumor suppression and cell mortality. Cell (1996) 11.41

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33

Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20

Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88

The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature (1999) 7.85

Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science (2001) 7.13

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med (1998) 6.83

The multiple roles of PTEN in tumor suppression. Cell (2000) 6.71

Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51

Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet (2001) 5.92

The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet (1997) 5.55

PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 4.90

Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol (1999) 4.42

The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene (2008) 4.39

Impaired Fas response and autoimmunity in Pten+/- mice. Science (1999) 4.25

Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05

Role of SUMO-1-modified PML in nuclear body formation. Blood (2000) 4.05

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83

Role of PML in cell growth and the retinoic acid pathway. Science (1998) 3.82

The transcriptional role of PML and the nuclear body. Nat Cell Biol (2000) 3.80

PML is essential for multiple apoptotic pathways. Nat Genet (1998) 3.75

Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med (2001) 3.62

Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet (1998) 2.97

The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene (1995) 2.80

Genetic alterations in bladder cancer. Lancet (1993) 2.73

Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination In vivo. J Exp Med (1997) 2.71

Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell (1996) 2.66

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst (1998) 2.64

Catalytic subunit of DNA-dependent protein kinase: impact on lymphocyte development and tumorigenesis. Proc Natl Acad Sci U S A (1999) 2.58

BCL-6 regulates chemokine gene transcription in macrophages. Nat Immunol (2000) 2.58

The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell (1991) 2.56

Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene (1990) 2.50

Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res (2001) 2.48

Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev (1997) 2.47

Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A (1997) 2.47

Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J (2000) 2.38

Growth of a pure population of mouse mast cells in vitro with conditioned medium derived from concanavalin A-stimulated splenocytes. Proc Natl Acad Sci U S A (1981) 2.33

Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst (1995) 2.25

The function of PML in p53-dependent apoptosis. Nat Cell Biol (2000) 2.24

Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med (1997) 2.21

Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest (2001) 2.20

Ku70: a candidate tumor suppressor gene for murine T cell lymphoma. Mol Cell (1998) 2.18

Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A (1985) 2.14

Plzf regulates limb and axial skeletal patterning. Nat Genet (2000) 2.14

Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res (1993) 2.14

Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer (1997) 2.13

Acute promyelocytic leukemia: from genetics to treatment. Blood (1994) 2.09

Categorizing breast mammographic density: intra- and interobserver reproducibility of BI-RADS density categories. Breast (2005) 2.06

Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol (2001) 2.06

HIV antigen in the brains of patients with the AIDS dementia complex. Ann Neurol (1987) 2.04

Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 2.02

Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest (2001) 2.00

A role for PML and the nuclear body in genomic stability. Oncogene (1999) 1.97

The theory of APL revisited. Curr Top Microbiol Immunol (2007) 1.96

Transcriptional repression of Stat6-dependent interleukin-4-induced genes by BCL-6: specific regulation of iepsilon transcription and immunoglobulin E switching. Mol Cell Biol (1999) 1.91

The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol (1992) 1.91

Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci U S A (1991) 1.90

Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res (1990) 1.90

Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res (2000) 1.87

Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology (1985) 1.86

Expression of ras proto-oncogene proteins in normal human tissues. Oncogene (1987) 1.86

Murine embryonic stem cells without pig-a gene activity are competent for hematopoiesis with the PNH phenotype but not for clonal expansion. J Clin Invest (1997) 1.86

Evidence for BLM and Topoisomerase IIIalpha interaction in genomic stability. Hum Mol Genet (2001) 1.85

Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin Chem (2000) 1.85

An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res (2000) 1.85

Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82

Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature (1998) 1.82

Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med (1986) 1.79

A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Nat Genet (1999) 1.78

Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res (2000) 1.75

p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). J Exp Med (2001) 1.73

Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood (1997) 1.69

Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res (1998) 1.68

Regulation of apoptosis by PML and the PML-NBs. Oncogene (2008) 1.67

Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ (2009) 1.67

Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med (1987) 1.65

Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med (2001) 1.63

Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst (1999) 1.63

Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer (1997) 1.62

Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene (1992) 1.59

Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A (2000) 1.57

Quantification of PML-RAR alpha transcripts in acute promyelocytic leukaemia: explanation for the lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia-specific mRNA by alpha interferon. Br J Haematol (1996) 1.56

Intravenous basic fibroblast growth factor protects the lung but not mediastinal organs against radiation-induced apoptosis in vivo. Cancer J Sci Am (2006) 1.56

Myogenic regulatory protein expression in adult soft tissue sarcomas. A sensitive and specific marker of skeletal muscle differentiation. Am J Pathol (1994) 1.55

Desmoid fibromatosis is a clonal process. Hum Pathol (1996) 1.54

The chromosome make-up of mouse embryonic stem cells is predictive of somatic and germ cell chimaerism. Transgenic Res (1997) 1.54

Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst (1994) 1.52

Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res (1994) 1.50

p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci U S A (1999) 1.48

Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins. J Biol Chem (1998) 1.48

Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem (1994) 1.47

PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J (2001) 1.47

Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J Exp Med (1990) 1.47

Increased sensitivity to complement and a decreased red blood cell life span in mice mosaic for a nonfunctional Piga gene. Blood (1999) 1.46

Mzf1 controls cell proliferation and tumorigenesis. Genes Dev (2001) 1.43